Chris Shively

Chris Shively is an experienced financial professional with a robust background in corporate finance and investment management. From May 2005 to September 2022, Chris worked at Merck, serving as Director of Corporate Financial Evaluation & Analysis, where responsibilities included financial valuation and due diligence for various corporate transactions. As Director of US Oncology Finance, Chris developed revenue forecasts for KEYTRUDA and provided analytics for its strategic planning. Earlier roles included Associate Director of Pension Investments, managing substantial assets for US pension plans, and positions as an Equity Research Associate, where Chris analyzed financial statements and communicated investment strategies. Chris completed an MBA in Corporate Finance and Investment Management at UNC Kenan-Flagler Business School and holds a BS in Business from Wake Forest University.